2nd Quarter 2022

FUNDRAISING

Hemera’s fundraising activities continue through the Proemera investment syndicate. The next capital increase is scheduled for the end of July and with this important goal, Hemera will exceed a total of € 2,000,000 in capital raised. It is an extraordinary result of which we are proud and for which we sincerely thank all the investors, for financial support and trust, together with the group of scientists and the management team, for the tireless work.

CLASSIFICAZIONE ATMPS – ADVANCED THERAPY MEDICAL
PRODUCTS (ATMP) DESIGNATION

Hemera’s THEM therapy classification as Advanced Cell Therapy has been accepted by the EMA – European Medicine Agency. This is a very important stage in the regulatory approval process as this designation will provide the recognition that the therapy has a pharmaceutical grade product quality and meets the scientific standards and quality criteria imposed by the Regulatory Agency.

WORKSHOP

On June 24-25, the Hemera’s Team organized a workshop in Como reserved for neurosurgery and neurorehabilitation specialists, in order to interact with experts from centers of excellence located in Central and Northern Italy and to get to the heart of the clinical phase.

The feedback from the experts was very positive and stimulating and sanctioned the beginning of an effective collaboration. An early work plan with defined times and objectives was outlined, specifically the organization of a retrospective observational study to be completed by the end of 2022 and of a prospective observational study which will start in the first quarter of 2023. Experts from the spinal units of Milan, Brescia, Bergamo, Novara, and Varese participated to the workshop.

INTERNAL AND GOVERNANCE REORGANIZATION

In May-June, Hemera began an internal review, with the intention of responding at best to the complexity of the development and evaluation of the therapy in a clinical context.

This review led to some changes within both the scientific team and the area of ​​governance; in particular, Dr. Cristiana Vignoli has assumed the position of new Chief Executive Officer, taking over from Eng. Aldo Cocchiglia, whom we warmly thank for the work carried out this year as CEO and for his willingness to continue to follow Hemera’s growth as a board member.